Expression and export of angiogenesis inhibitors as immunofusins
US8206718B2 · kind B2 · utility
2Cited by
2References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 27, 2006 |
| Grant date | Jun 26, 2012 |
| Priority date | — |
| Expiry date | Jun 14, 2030 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/81
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A homodimeric protein of the invention has angiogenesis inhibiting activity. The homodimeric protein consists of two identical fusion proteins bound together as a homodimer. Each fusion protein comprises an immunoglobulin Fc region and a first target protein linked to the immunoglobulin Fc region. The first target protein has an angiogenesis inhibiting activity of angiostatin or endostatin, and is selected from the group consisting of a plasminogen fragment and a collagen XVIII fragment. The immunoglobulin Fc region comprises a hinge region, a CH2 region, and a CH3 region.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.